Literature DB >> 10344921

Modelling different approaches to the management of upper gastrointestinal disease.

A K Duggan1.   

Abstract

A treatment algorithm for the management of upper gastrointestinal (UGI) disease in general practice has been developed by an international group of general practitioners [the International Gastro Primary Care Group (IGPCG)]. When the algorithm was evaluated to consider the overall cost per patient, it was shown to offer savings over current practice in the UK. Adjustments to the algorithm have been proposed, usually on the basis of variations in the place and timing of Helicobacter pylori testing and eradication, with or without endoscopy. This paper evaluates the current cost of UGI disease in the UK, the base IGPCG algorithm and the 5 major alternative scenarios. The original IGPCG algorithm was the least costly option of all those considered, with additional H. pylori testing for all patients with suspected ulcer being the second least expensive option. Routine endoscopies for all patients or for all patients aged more than 45 years were the most expensive scenarios and would require a 16- or 13-fold increase, respectively, in the provision of endoscopy services in the UK. The use of routine endoscopy for all patients aged more than 45 years who were presenting with UGI symptoms for the first time was a mid-priced option, but would still require a 5-fold increase in the provision of endoscopy services. The modelling process highlights the fact that early stratification of patients into diagnostic and treatment groups, on the basis of history and symptom cluster, is a less costly approach than that of early routine endoscopy or H. pylori testing. If H. pylori testing is to be used routinely, then the least costly way is to apply the method to those patients who have symptoms that are more indicative of ulcer disease. All the scenarios considered resulted in lower drug costs than current average UK drug costs per patient per year, and in fewer prescriptions and general practitioner surgery visits per patient. There are several ways in which the management of UGI disease in the UK could be improved with regard to costs and resource utilisation, some of which are presented here. This process emphasises the value of modelling techniques to investigate the consequences of different patient management scenarios.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10344921     DOI: 10.2165/00019053-199814002-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  6 in total

1.  Consensus guidelines for evaluating and treating patients with upper gastrointestinal symptoms in the primary care setting.

Authors:  M J Whitaker
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

Review 2.  Development of an economic model for the management of upper gastrointestinal disease in primary care. Preliminary findings.

Authors:  A Haycox; M Butterworth; T Walley; S Barton
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

Review 3.  Management of dyspepsia in general practice. A critical assessment.

Authors:  C Tosetti; V Stanghellini
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

4.  Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age.

Authors:  A H Briggs; M J Sculpher; R P Logan; J Aldous; M E Ramsay; J H Baron
Journal:  BMJ       Date:  1996-05-25

5.  Dyspepsia in England and Scotland.

Authors:  R H Jones; S E Lydeard; F D Hobbs; J E Kenkre; E I Williams; S J Jones; J A Repper; J L Caldow; W M Dunwoodie; J M Bottomley
Journal:  Gut       Date:  1990-04       Impact factor: 23.059

6.  Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: a decision analysis.

Authors:  M D Silverstein; T Petterson; N J Talley
Journal:  Gastroenterology       Date:  1996-01       Impact factor: 22.682

  6 in total
  2 in total

1.  Computer modelling. The need for careful evaluation and public audit.

Authors:  A Maynard; R F Cookson
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

Review 2.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.